Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Biomedicines ; 12(5)2024 May 08.
Artículo en Inglés | MEDLINE | ID: mdl-38790995

RESUMEN

Post-irradiation xerostomia remains a significant quality of life concern for patients with head and neck cancers. Conventional therapies offer limited effectiveness. This study aims to investigate the therapeutic potential of office-based salivary ductal steroid irrigation in patients with post-irradiation xerostomia. This single-center observational study recruited 147 head and neck cancer patients suffering from post-irradiation xerostomia between November 2020 and October 2022. All included subjects received at least one round of successful salivary ductal cannulation and irrigation. The primary measure of efficacy was improvement in subjective xerostomia and objective salivary amylase levels. A logistic regression was employed to evaluate factors affecting treatment responsiveness. The response rate among nasopharyngeal cancer (NPC) patients was 74.8%, and that among non-NPC cancer was 65.6%, without significant intergroup differences. The statistical analysis revealed no significant influence of age, gender, or disease stage on treatment responsiveness. Post-treatment salivary amylase levels were significantly higher in responsive non-NPC patients. In conclusion, salivary ductal steroid irrigation emerged as a promising therapeutic modality for the management of post-irradiation xerostomia in head and neck cancer patients. While no explicit factors were predictive of responsiveness, the high rate of symptom improvement suggests that this therapy may be a viable alternative for patients that are refractory to standard treatments.

2.
Lab Chip ; 24(12): 3112-3124, 2024 Jun 11.
Artículo en Inglés | MEDLINE | ID: mdl-38758131

RESUMEN

Microfluidic dispensing technologies often require additional equipment, posing challenges for their integration into point-of-care testing (POCT) applications. In response to this challenge, we have developed a pipette-operable microfluidic device fabricated using 3D printing technology for precise liquid dispensing. This device features three reaction chambers and three distinct hydrophobic valves to control the flow direction of liquids. Through these valves, the pipette-operable microfluidic device can sequentially dispense and isolate the liquid into the three reaction chambers, allowing for the individual conduction of three distinct reactions. These hydrophobic valves, with optimized flow resistance and burst pressure, can sustain a volumetric flow rate of up to 25 µL s-1, making them compatible with a standard pipette, a syringe, or a dropper operation. Furthermore, the device is successfully used to operate with various liquids, including BSA, DMEM, FBS, plasma, and blood, representing that the device has the potential to be used for various applications. Additionally, distinct RT-LAMP primer sets have been incorporated for diagnosing SARS-CoV-2, influenza A, and influenza B within each chamber through lyophilization. This pipette-operable microfluidic device serves as a versatile tool for diagnosing these three diseases using a single loading process, with results readable by the naked eye or image assay within 30 minutes of incubation. Finally, the design concepts are extended to engineer a microfluidic device with 20 reaction chambers, offering significant potential for multi-disease diagnostics.


Asunto(s)
Interacciones Hidrofóbicas e Hidrofílicas , Dispositivos Laboratorio en un Chip , SARS-CoV-2 , Humanos , SARS-CoV-2/aislamiento & purificación , Diseño de Equipo , COVID-19/diagnóstico , COVID-19/virología , Pruebas en el Punto de Atención , Técnicas de Amplificación de Ácido Nucleico/instrumentación , Técnicas Analíticas Microfluídicas/instrumentación , Impresión Tridimensional
3.
Life Sci ; 347: 122627, 2024 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-38614301

RESUMEN

A high mortality rate makes hepatocellular carcinoma (HCC) a difficult cancer to treat. When surgery is not possible, liver cancer patients are treated with chemotherapy. However, HCC management and treatment are difficult. Sorafenib, which is a first-line treatment for hepatocellular carcinoma, initially slows disease progression. However, sorafenib resistance limits patient survival. Recent studies have linked HCC to programmed cell death, which has increased researcher interest in therapies targeting cell death. Pyroptosis, which is an inflammatory mode of programmed cell death, may be targeted to treat HCC. Pyroptosis pathways, executors, and effects are examined in this paper. This review summarizes how pyroptosis affects the tumor microenvironment (TME) in HCC, including the role of cytokines such as IL-1ß and IL-18 in regulating immune responses. The use of chemotherapies and their ability to induce cancer cell pyroptosis as alternative treatments and combining them with other drugs to reduce side effects is also discussed. In conclusion, we highlight the potential of inducing pyroptosis to treat HCC and suggest ways to improve patient outcomes. Studies on cancer cell pyroptosis may lead to new HCC treatments.


Asunto(s)
Carcinoma Hepatocelular , Neoplasias Hepáticas , Piroptosis , Microambiente Tumoral , Humanos , Carcinoma Hepatocelular/patología , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/metabolismo , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/metabolismo , Animales , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Sorafenib/uso terapéutico , Sorafenib/farmacología
4.
Materials (Basel) ; 17(5)2024 Mar 03.
Artículo en Inglés | MEDLINE | ID: mdl-38473652

RESUMEN

Geopolymers (GPs) are gaining prominence due to their low carbon emissions and sustainable attributes. However, one challenge with GPs, particularly those made with ground granulated blast furnace slag (GGBFS), is their significant shrinkage during the geopolymerization process, limiting its practical applicability. This study focuses on how the substitution ratio of metakaolin (MK) and the concentration of sodium hydroxide (NaOH) in the activator can influence the shrinkage and strength of a GGBFS-based GP. The experimental approach employed a 3 × 3 parameter matrix, which varied MK substitution ratios (0%, 50%, and 100%) and adjusted the NaOH concentration (6 M, 10 M, and 14 M). The results revealed that increasing MK substitution, particularly with 6 M NaOH activation, reduced the GP shrinkage but also diminished compressive strength, requiring higher NaOH concentrations for strength improvement. Statistical tools, including analysis of variance (ANOVA) and second-order response surface methodology (RSM), were employed for analysis. ANOVA results indicated the significant impacts of both the MK content and NaOH concentration on compressive strength, with no observable interaction. However, the shrinkage exhibited a clear interaction between MK content and NaOH concentration. The RSM model accurately predicted compressive strength and shrinkage, demonstrating a high predictive accuracy, for which the coefficients of determination (R2) were 0.99 and 0.98, respectively. The model provides a reliable method for determining the necessary compressive strength and shrinkage for GGBFS-based GP based on MK substitution and NaOH concentration. Within the optimization range, the RSM model compared with experimental results showed a 6.04% error in compressive strength and 0.77% error in shrinkage for one interpolated parameter set. This study establishes an optimized parameter range ensuring a GP performance that is comparable to or surpassing OPC, with a parameter set achieving a compressive strength of 34.9 MPa and shrinkage of 0.287% at 28 days.

5.
Cancers (Basel) ; 16(2)2024 Jan 11.
Artículo en Inglés | MEDLINE | ID: mdl-38254808

RESUMEN

BACKGROUND AND AIM: Transcatheter liver-directed intra-arterial therapies are mainstream treatment options for intermediate-stage hepatocellular carcinoma (HCC). However, the effect of low skeletal muscle mass (LSMM) on overall survival (OS) in these patients remains uncertain. We aimed to ascertain the prevalence and prognostic effect of LSMM in this population. METHOD: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a comprehensive search was performed in the PubMed and Embase databases until Oct 2023. Random-effects meta-analysis was performed to determine the pooled prevalence of LSMM and calculate the hazard ratio (HR) for OS with a 95% confidence interval (CI) in patients with intermediate-stage HCC undergoing various transarterial therapies, comparing those with and without LSMM. RESULTS: Twelve studies involving 2450 patients were included. The pooled prevalence of LSMM was 46% (95% CI, 38-55%), and the results were consistent across different treatments, regions, and age subgroups. The meta-analysis indicated that LSMM was significantly associated with decreased OS (HR, 1.78; 95% CI, 1.36-2.33; I2, 75%). Subgroup analyses reassured the main findings across various therapies, including transarterial chemoembolization (TACE) (HR, 1.68; 95% CI, 1.23-2.30; I2, 81%), transarterial embolization (TAE) (HR, 2.45; 95% CI, 1.42-4.22; I2, 0%), and transarterial radioembolization (TARE) (HR, 1.94; 95% CI, 1.01-3.73; I2, 0%). CONCLUSIONS: In intermediate-stage HCC, LSMM is common and associated with reduced OS. To achieve an optimal prognosis, clinicians should incorporate routine LSMM measurement into practice, while caring for patients with intermediate-stage HCC, irrespective of TACE, TAE, and TARE.

6.
Front Neurol ; 14: 1322199, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38192578

RESUMEN

Purpose: This study aimed to examines the long-term trend of incidence of peripheral vestibular disorders between 2010 and 2018 in Taiwan. Methods: Study-eligible patients were identified from Taiwan's Longitudinal Health Insurance Database 2005 maintained by the Ministry of Health and Welfare in Taiwan. We retrieved 230,566 patients with a first-time diagnosis of peripheral vestibular disorders between 2010 and 2018. We calculated annual incidence rates of peripheral vestibular disorders per 100,000 population. We used the annual percent change (APC) to test the trend of peripheral vestibular disorders over time. Results: The mean annual incidence rate of peripheral vestibular disorders during the study period was 1489.6 per 100,000 population. Incidence showed a statistically significant steady decrease from 2010 to 2018 with a mean APC of -6.15% (95% CI = -6.97% ~ -5.32%). The decline was led by Meniere's disease (APC = -9.83, 95% CI = -10.66% ~ -8.99%), followed by benign paroxysmal positional vertigo (APC = -3.69, 95% CI = -4.53% ~ -3.03%), vestibular neuritis (APC = -7.85, 95% CI = -8.96 ~ -6.73), and other peripheral vestibular dizziness (APC = -5.56, 95% CI = -6.69% ~ -4.43%). Conclusion: The incidence of peripheral vestibular disorders, overall, and the four major subgroups, benign paroxysmal positional vertigo, Meniere's disease, vestibular neuritis, and other peripheral vestibular dizziness, all decreased substantially, year by year within the 2010-2018 period.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA